Pulse Biosciences, Inc. (PLSE)

Pulse Biosciences' stock experienced several notable events over the past six months. The company reported Q4 2025 financial results with increased revenue but a GAAP net loss. Positive clinical data for the nPulse Cardiac Catheter System was presented at the AF Symposium in January 2026 and Heart Rhythm 2026 in April 2026. The company commenced enrollment in the NANOPULSE-AF U.S. IDE pivotal clinical trial in early April 2026. Q1 2026 revenue was reported at $0.4 million, missing consensus expectations, with a wider GAAP net loss. Insider purchases were authorized under an equity program, and the stock was upgraded to a Zacks Rank #2 (Buy). The stock price increased by 24.12% over the past six months but experienced recent volatility.

Information regarding the specific demand seasonality for Pulse Biosciences, Inc.'s products and services was not found in the provided search results.

Pulse Biosciences, Inc. is a bioelectric medicine company focused on health innovation through its Nano-Pulse Stimulation (NPS) technology. The company's major products include the CellFX® System, nPulse System, nPulse Vybrance Percutaneous Electrode system, nPulse Cardiac Surgical Clamp, nPulse Cardiac Catheter System, and nPulse Console. The company is expanding its strategic focus to cardiovascular applications, with potential expansion into other medical specialties.

Pulse Biosciences, Inc. is headquartered in Miami, Florida, and expanded its operations and sales into Europe and Canada in 2021. The company has a presence in North America and the United States, with some sales in the "Rest of World".

Pulse Biosciences has a positive internal brand reputation, with 94% of employees stating it is a great place to work. The company's news sentiment score is approximately 0.46, suggesting a somewhat neutral to slightly positive media sentiment.

Pulse Biosciences is owned by a mix of institutional shareholders, insiders, and retail investors. Institutional ownership accounts for 9.30% (or 76.95%) of the stock, with major holders including BlackRock, Inc. and Vanguard Group Inc. Insider ownership accounts for 81.37% (or 74.60%) of the stock, with Robert W. Duggan being the largest individual shareholder. Retail investors own 9.33% of the company.